Sandoz Reaches $275 Million Settlement in US Generic Drug Price Fixing Case

Settlement Amount:
Sandoz has agreed to pay $275 million to settle claims with end payer plaintiffs in the US generic drug antitrust class action litigation14.

Previous Settlements:
This follows a $265 million settlement with direct purchaser plaintiffs in February 2024 and earlier settlements with the US Department of Justice in 2020 and 202112.

Provision for Remaining Claims:
Sandoz has taken a provision of $265 million for outstanding claims brought by opt-out plaintiffs and State Attorneys' General1.

No Admission of Wrongdoing:
The settlement does not include an admission of wrongdoing by Sandoz12.

Settlement Terms:
The agreement covers alleged conduct between 2009 and 2019 and includes a broad release of claims for all medicines at issue in the end purchaser class claims1.

Opt-Out Option:
Class members have the right to opt out of the settlement, which could result in the settlement amount being reduced by up to $45 million1.

Court Approval:
The settlement is subject to court approval, and class members will be notified and given the opportunity to opt out, object, or file a claim for a settlement payment1.

Sources:

1. https://www.globenewswire.com/news-release/2024/12/17/2997976/0/en/Sandoz-takes-further-steps-to-resolve-legacy-US-Generic-Drug-Antitrust-Class-Action-Litigation.html

2. https://www.fiercepharma.com/pharma/sandoz-ponies-265m-settle-lingering-price-fixing-case

4. https://www.law360.com/corporate/articles/2275003/sandoz-cuts-275m-deal-for-more-price-fixing-claims